Efficacy and safety of additional use of tacrolimus in patients with early rheumatoid arthritis with inadequate response to DMARDs-a multicenter, double-blind, parallel-group trial

Modern Rheumatology

Volumn 21, Issue 5, 2011, Pages 458-468

  Kawai, Shinichi ^a   Takeuchi, Tsutomu ^b   Yamamoto, Kazuhiko ^c   Tanaka, Yoshiya ^d   Miyasaka, Nobuyuki ^e  

^a TOHO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

DMARD; Randomized controlled trial; Rheumatoid arthritis; Tacrolimus

Indexed keywords

BUCILLAMINE; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS;

ADULT; ARTICLE; BLOOD DISEASE; BREAST DISEASE; CONGENITAL DISORDER; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FAMILIAL DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENETIC DISORDER; HEPATOBILIARY DISEASE; HUMAN; INFECTION; INJECTION SITE REACTION; INJURY; INTOXICATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; REPRODUCTIVE TOXICITY; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SKIN DISEASE; SOFT TISSUE DISEASE; URINARY TRACT DISEASE; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYSTEINE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JOINTS; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SULFASALAZINE; TACROLIMUS; TREATMENT OUTCOME;

EID: 84855711892     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0425-8     Document Type: Article

References (37)

1. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992;35(7):729-35.
2. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNFalpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130(7):1655-63. (Pubitemid 30611945)
3. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol. 2001;1(4):749-57. (Pubitemid 32206535)
4. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40(9):1256-65. (Pubitemid 17138110)
5. Miyahara H, Hotokebuchi T, Arita C, Arai K, Sugioka Y, Takagishi K, et al. Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. Clin Immunol Immunopathol. 1991;60(2):278-88.
6. Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y, et al. FK506 is superior to methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm Res. 2001;50(10):509-14. (Pubitemid 32999714)
7. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, et al. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol. 2004;31(2):243-51. (Pubitemid 38160744)
8. Kawai S, Hashimoto H, Kondo H, Murayama T, Kiuchi T, Abe T. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. J Rheumatol. 2006;33(11):2153-61. Epub 2006 Sep 1. (Pubitemid 44749772)
9. Kremer JM, Habros JS, Kolba KS, Kaine JL, Borton MA, Mengle-Gaw LJ, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: A six-month, open-label study. Arthritis Rheum. 2003;48(10):2763-8. (Pubitemid 37280603)
10. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6):762-84. (Pubitemid 351847559)
11. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989;16(5):585-91. (Pubitemid 19154397)
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24. (Pubitemid 18091653)
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-35.
14. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44-8.
15. vanGestelAM, PrevooML, van 'T HofMA, van RijswijkMH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 1996;39(1):34-40. (Pubitemid 26036375)
16. Fransen J, Creemers MC, Van Riel PL. Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford). 2004 43(10) 1252-5. (Pubitemid 39359299)
17. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum. 1983;26(11):1346-53. (Pubitemid 14231480)
18. van der Heijde DM. Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol. 1996;10(3):435-53.
19. van der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: Guidelines from a roundtable discussion. Arthritis Rheum. 2002;47(2):215-8. (Pubitemid 34303850)
20. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81. (Pubitemid 38296553)
21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003;48(1):35-45. (Pubitemid 36091645)
22. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial ATTRACT Study Group. Lancet. 1999;354(9194): 1932-9.
23. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007; 370(9602):1861-74. (Pubitemid 350180008)
24. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):65-9.
25. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631-7.
26. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162-7. (Pubitemid 47309731)
27. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum. 2004;50(11):3432-43. (Pubitemid 39488667)
28. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000;43(3):495-505. (Pubitemid 30394939)
29. Kerstens PJ, Boerbooms AM, Jeurissen ME, de Graaf R, Mulder J, van de Putte LB. Radiological and clinical results of longterm treatment of rheumatoid arthritis with methotrexate and azathioprine. J Rheumatol. 2000;27(5):1148-55. (Pubitemid 30262497)
30. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydoxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1(8646):1036-8. (Pubitemid 19123055)
31. Akimoto K, Kusunoki Y, Nishio S, Takagi K, Kawai S. Safety profile of tacrolimus in patients with rheumatoid arthritis. Clin Rheumatol. 2008;27(11):1393-7.
32. Kawai S, Tanaka K, Ohno I, Utsunomiya K, Seino Y. Safety of long-term tacrolimus therapy for rheumatoid arthritis: An openlabel, uncontrolled study in non-elderly patients. Mod Rheumatol. 2008;18(4):345-53.
33. Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002;46(8):2020-8.
34. Yocum DE, Furst DE, Bensen WG, Burch FX, Borton MA, Mengle-Gaw LJ, et al. Safety of tacrolimus in patients with rheumatoid arthritis: Long-term experience. Rheumatology (Oxford). 2004 43(8) 992-9. (Pubitemid 39144446)
35. Yocum DE, Furst DE, Kaine JL, Baldassare AR, Stevenson JT, Borton MA, Tacrolimus Rheumatoid Arthritis Study Group, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial. Arthritis Rheum. 2003;48(12): 3328-37. (Pubitemid 37531899)
36. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990;33(1):9-18. (Pubitemid 20040125)
37. Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1993;36(6):795-803. (Pubitemid 23175621)